Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2016

Open Access 01-12-2016 | Research article

Neighborhood socioeconomic characteristics and statin medication in patients with myocardial infarction: a Swedish nationwide follow-up study

Authors: Per-Ola Forsberg, Xinjun Li, Kristina Sundquist

Published in: BMC Cardiovascular Disorders | Issue 1/2016

Login to get access

Abstract

Background

Coronary heart disease (CHD) and myocardial infarction (MI) are associated with neighborhood-level socioeconomic status (SES). Statins are important drugs for secondary prevention of MI. However, no study has determined whether neighborhood-level SES is associated with statin medication in MI patients. We aimed to determine whether there is a difference in statin medication rate in MI patients across different levels of neighborhood SES.

Methods

All patients in Sweden, diagnosed with incident MI from January 1st, 2000 until December 31st 2010, were followed (n = 116,840). Of these, 89.7 % received statin medication. Data were analyzed by multilevel logistic regression, with individual-level characteristics (age, marital status, family income, educational attainment, country of origin, urban/rural status and comorbidities/chronic conditions related to MI) as covariates.

Results

Low neighborhood-level SES was significantly associated with low statin medication rate (Odds Ratio 0.80). In the full model, which took into account individual-level socioeconomic characteristics and MI comorbidities, the odds no longer remained significant.

Conclusions

Individual-level approaches may be most important in health care policies regarding statin medication in MI patients.
Appendix
Available only for authorised users
Literature
1.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.CrossRefPubMed
2.
Lynch JW, Kaplan GA, Cohen RD, Tuomilehto J, Salonen JT. Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol. 1996;144:934–42.CrossRefPubMed
3.
Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:Cd004816.
4.
Group Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
5.
6.
Sundquist K, Winkleby M, Ahlen H, Johansson SE. Neighborhood socioeconomic environment and incidence of coronary heart disease: a follow-up study of 25,319 women and men in Sweden. Am J Epidemiol. 2004;159:655–62.CrossRefPubMed
7.
Cubbin C, Sundquist K, Ahlen H, Johansson SE, Winkleby MA, Sundquist J. Neighborhood deprivation and cardiovascular disease risk factors: protective and harmful effects. Scand J Public Health. 2006;34:228–37.CrossRefPubMed
8.
Sundquist K, Malmstrom M, Johansson SE. Neighbourhood deprivation and incidence of coronary heart disease: a multilevel study of 2.6 million women and men in Sweden. J Epidemiol Community Health. 2004;58:71–7.CrossRefPubMedPubMedCentral
9.
Sundquist K, Li X. Coronary heart disease risks in first- and second-generation immigrants in Sweden: a follow-up study. J Intern Med. 2006;259:418–27.CrossRefPubMed
10.
Kawakami N, Winkleby M, Skog L, Szulkin R, Sundquist K. Differences in neighborhood accessibility to health-related resources: a nationwide comparison between deprived and affluent neighborhoods in Sweden. Health Place. 2011;17:132–9.CrossRefPubMed
11.
Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.CrossRefPubMedPubMedCentral
12.
Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7:787–91.CrossRefPubMed
13.
Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby B. Reliability of the hospital registry. The diagnostic data are better than their reputation. Lakartidningen. 1994;91(598):603–5.
14.
Zöller B, Li X, Sundquist J, Sundquist K. Neighborhood deprivation and hospitalization for venous thromboembolism in Sweden. J Thromb Thrombolysis. 2012;34:374–82.CrossRefPubMed
15.
Zöller B, Li X, Sundquist J, Sundquist K. Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden. Europace. 2013;15:1119–27.CrossRefPubMed
16.
Li X, Sjöstedt C, Sundquist K, Zöller B, Sundquist J. Neighborhood deprivation and childhood autism: a nationwide study from Sweden. J Psychiatr Res. 2014;53:187–92.CrossRefPubMed
17.
Sundquist J, Johansson SE, Yang M, Sundquist K. Low linking social capital as a predictor of coronary heart disease in Sweden: a cohort study of 2.8 million people. Soc Sci Med. 2006;62:954–63.CrossRefPubMed
18.
Johnell K, Lindstrom M, Melander A, Sundquist J, Eriksson C, Merlo J. Anxiolytic-hypnotic drug use associated with trust, social participation, and the miniaturization of community: a multilevel analysis. Soc Sci Med. 2006;62:1205–14.CrossRefPubMed
19.
Johnell K, Lindstrom M, Sundquist J, Eriksson C, Merlo J. Individual characteristics, area social participation, and primary non-concordance with medication: a multilevel analysis. BMC Public Health. 2006;6:52.CrossRefPubMedPubMedCentral
20.
Sundquist K, Theobald H, Yang M, Li X, Johansson SE, Sundquist J. Neighborhood violent crime and unemployment increase the risk of coronary heart disease: A multilevel study in an urban setting. Soc Sci Med. 2006;62:2061–71.CrossRefPubMed
21.
Snijders PTABB, Bosker TABSRJ, Bosker PRJ. Multilevel analysis: an introduction to basic and advanced multilevel modeling: SAGE. 1999.
22.
Brooks JM, Cook EA, Chapman CG, Kulchaitanaroaj P, Chrischilles EA, Welch S, et al. Geographic variation in statin use for complex acute myocardial infarction patients: evidence of effective care? Med Care. 2014;52 Suppl 3:S37–44.CrossRefPubMed
23.
24.
Headen Jr AE, Masia NA, Axelsen KJ. Effects of medicaid access restrictions on statin utilisation for patients treated by physicians practising in poor and minority neighbourhoods. PharmacoEconomics. 2006;24 Suppl 3:41–53.PubMed
25.
Tuppin P, Ricci-Renaud P, de Peretti C, Fagot-Campagna A, Alla F, Danchin N, et al. Frequency of cardiovascular diseases and risk factors treated in France according to social deprivation and residence in an overseas territory. Int J Cardiol. 2014;173:430–5.CrossRefPubMed
26.
Thiebaud P, Patel BV, Nichol MB. The demand for statin: the effect of copay on utilization and compliance. Health Econ. 2008;17:83–97.CrossRefPubMed
27.
Carlsson A, Starrin B, Gigante B, Leander K, Hellenius M-L, de Faire U. Financial stress in late adulthood and diverse risks of incident cardiovascular disease and all-cause mortality in women and men. BMC Public Health. 2014;14:17.CrossRefPubMedPubMedCentral
28.
Carlsson AC, Wändell P, Gasevic D, Sundquist J, Sundquist K. Neighborhood deprivation and warfarin, aspirin and statin prescription - A cohort study of men and women treated for atrial fibrillation in Swedish primary care. Int J Cardiol. 2015;187:547–52.CrossRefPubMedPubMedCentral
29.
Pimenta E, Stowasser M. Uncontrolled hypertension: beyond pharmacological treatment. Hypertens Res. 2009;32:729–31.CrossRefPubMed
30.
Amstislavski P, Matthews A, Sheffield S, Maroko A, Weedon J. Medication deserts: survey of neighborhood disparities in availability of prescription medications. Int J Health Geogr. 2012;11:48.CrossRefPubMedPubMedCentral
31.
Campo G, Guastaroba P, Marzocchi A, Santarelli A, Varani E, Vignali L, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest. 2013;144:750–7.CrossRefPubMed
32.
Hanssen M, Cottin Y, Khalife K, Hammer L, Goldstein P, Puymirat E, et al. French registry on acute ST-elevation and non ST-elevation myocardial infarction 2010. FAST-MI 2010. Heart. 2012;98:699–705.CrossRefPubMedPubMedCentral
33.
34.
Goff DC, Gu L, Cantley LK, Sheedy DJ, Cohen SJ. Quality of care for secondary prevention for patients with coronary heart disease: results of the Hastening the Effective Application of Research through Technology (HEART) trial. Am Heart J. 2003;146:1045–51.CrossRefPubMed
35.
Johansen ME, Hefner JL, Foraker RE. Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. Am J Cardiol. 2015;115:1507–12.CrossRefPubMed
36.
Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, et al. Statin use in outpatients with obstructive coronary artery disease. Circulation. 2011;124:2405–10.CrossRefPubMedPubMedCentral
Metadata
Title
Neighborhood socioeconomic characteristics and statin medication in patients with myocardial infarction: a Swedish nationwide follow-up study
Authors
Per-Ola Forsberg
Xinjun Li
Kristina Sundquist
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2016
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-016-0319-y

Other articles of this Issue 1/2016

BMC Cardiovascular Disorders 1/2016 Go to the issue

Research article

The association of functional polymorphisms in genes encoding growth factors for endothelial cells and smooth muscle cells with the severity of coronary artery disease

Study protocol

A single-center randomized, controlled trial investigating the efficacy of a mHealth ECG technology intervention to improve the detection of atrial fibrillation: the iHEART study protocol

Research article

Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent

Research article

Psychometric evaluation of the Polish adaptation of the Hill-Bone Compliance to High Blood Pressure Therapy Scale

Research article

Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome

Research article

Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla® Flex II Occluder

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits